Key Takeaways
- Record revenue, steady margins: FY26 revenue crossed ₹900 cr for the first time, up 19% YoY, with adjusted EBITDA holding at 13.4%. The quarter extended the streak to 13 consecutive record quarters.
- Exports are the growth engine: The export vertical surged 40% in FY26 and 67% in Q4, validating years of regulatory investment, though management warns the business is binary and lumpy.
- Trade generics hit a pothole: Codeine product discontinuation and lumpy institutional orders dragged the segment; management is filling the gap with Ayurvedic and non-codeine alternatives but won't quantify the recovery.
- Plant 6 unlocks the next leg: Mechanical completion done, commercialization on track for H1 FY27, taking revenue capacity to ~₹1,000 cr with 10-15% upside from efficiency tweaks.
- What to watch next quarter: Plant 6 commercialization progress, whether export momentum sustains at the Q4 run rate, and any quantification of codeine-loss recovery in trade generics.
CDMO: The Core Growth Driver
- 20% growth, dependable partner: Generic Formulations CDMO hit ₹664 cr in FY26, with management citing strengthened positioning as a dependable and agile manufacturing partner for Indian pharma customers.
- Quality systems as moat: The company has built electronic quality management systems, calling itself one of the few Indian organizations to do so, which supports regulatory readiness and customer trust.
- R&D is customer-led plus own bets: Investments split between customer wish-list projects and proprietary development in therapeutic areas where the company sees strong potential demand. The goal is to be the first port of call for customers in chosen areas while retaining the flexibility to decline projects.
- Regulatory bar is rising: The regulator is upping standards around bioequivalence studies and Phase III/IV clinical trials, forcing the entire industry to rethink R&D pipelines, which management frames as an opportunity for compliant players.
Hitesh Windlass: "This is something that we've built in -- having this electronically is a big advantage, and we are one of the few organizations who have done it in the Indian market."
Exports: High Reward, Binary Risk
- 40% FY26 growth, 67% in Q4: The export vertical reached ₹46 cr for the full year and ₹17 cr in Q4, validating years of effort toward regulatory approvals and product registrations.
- Philippines approval opens doors: The injectable facility received GMP certification from the Philippines, a market where margin realizations are higher, and management sees it as a stepping stone to other ROW markets including Southeast Asia, CIS countries, and Africa using the same dossier and plant approvals.
- Binary by nature: Management cautioned that the export business requires long investment periods and results are often binary; many efforts yield little revenue, and when they do, it takes more time than other verticals. The company continues to invest because it is a high-margin vertical.
- No run-rate guidance: When asked if the Q4 export number represents a sustainable quarterly run rate, management declined to guide, citing policy.
Trade Generics & Institutional: Absorbing the Codeine Shock
- 13% growth masked a Q3-Q4 drag: The segment grew to ₹195 cr in FY26, but Q3 and Q4 were affected by codeine product discontinuation and the lumpy nature of institutional business.
- Codeine exit reshapes the portfolio: Two of the largest brands in the Indian pharma market, owned by multinationals, exited the market due to regulatory oversight on codeine-based cough syrups. The company is adding Ayurvedic and non-codeine cough syrups, plus other liquid products like liver enzyme supplements and Lactulose solutions, with some pickup already visible in Q4.
- Recovery quantification withheld: Management declined to specify what percentage of the codeine business loss has been compensated, saying the overall scheme of business should be looked at instead.
- Long-term thesis intact: Management cited favourable macroeconomic factors, increasing demand for affordable healthcare, the AAA strategy, geographic expansion, portfolio expansion, and new institutional accounts as structural supports, though the short-term trajectory was not specified.
Capacity & Capital Allocation
- Plant 6 ready for H1 FY27: Mechanical completion achieved; commercialization remains on track for the first half of FY27. Combined with existing capacity, the company can deliver about ₹1,000 cr in revenue, excluding injectables at ₹100 cr, with 10-15% upside potential through efficiency tweaks as the plant commercializes.
- No organic capex in FY27: Beyond maintenance capex, no new organic capacity investment is planned for FY27. If the company delivers very good numbers, additional capacity may come in FY28.
- 1.5-to-2.5-year capex chunks: The company deliberately avoids building 5-year capacity, preferring smaller, faster chunks. When capacity utilization reaches around 60%, they start building the next block.
- Working capital discipline sustained: Working capital days reduced from around 40 days to 20-25 days, maintained for about three years through organization-wide financial discipline. Management expects no significant variation from current levels.
- Balance sheet strength: The business generated ₹105 cr in net operating cash flows and closed the year with net liquidity of ₹251 cr. A ₹47 cr buyback was completed without promoter participation, and a ₹13 cr dividend has been proposed.
Hitesh Windlass: "We do not want -- or we do not see ourselves doing a capex, which is like 5 years kind of we're creating capacity for the next 5 years. We want to do it more like 1.5 to 2.5 years kind of chunk. And that's the sweet spot that we believe is most suitable for us."
New Dosage Forms & Inorganic Strategy
- Injectables scaling in line: The injectables business is catching up to where management wants it to be, with the Philippines approval providing a foothold in higher-margin export markets.
- GLP-1: watching, not committing: The company is watching the GLP-1 space keenly and wants to position as a viable option for filling vials as volumes pick up and current players need CDMO partners. However, no trade generic pipeline is planned for GLP-1 because prescriptions are substituted by retailers and the category remains a metro phenomenon. The regulatory action banning injectables marketed as beauty products adds a layer of caution.
- Dosage form gaps identified, no plans finalized: The company is absent from ointments, steroids, beta-lactam antibiotics, soft-gel hormones, and eye drops, with very small capacities in protein powders and nutraceuticals. Management sees dosage form expansion serving all three verticals as important but has not finalized any organic building plan and is not at peak capacity utilization to justify another addition right now.
- Inorganic filter: good business, no problems: The company filters acquisition ideas for established businesses with room to grow and is willing to pay a premium. It will not buy into somebody else's problem even at a cheap price, citing the unknown depth of issues in a turnaround.
Hitesh Windlass: "One of the things that has been very important discipline for us has been that we don't want to walk into somebody else's problem. Even if it is coming for a very cheap price because a lot of effort goes into fixing something that is really -- you don't know the depth of it when you are buying a new -- into a new business."
Margins & Cost Environment
- Adjusted EBITDA steady at 13.4%: FY26 adjusted EBITDA margin was 13.4%, with Q4 at 13.6% after adjusting for ESOP costs. Reported EBITDA grew 11% to ₹105 cr, and reported PAT rose 9% to ₹66 cr.
- Long-run margin expectation is up: Management stated that operational EBITDA, excluding ESOP expenses, has improved significantly and expects the overall EBITDA level to grow over the long run.
- API cost pass-through varies by vertical: Supply disruptions and price increases from the West Asia crisis and fuel price surge are being managed differently across segments. In CDMO, open cost sheets mean increases are discussed transparently with customers. In trade generics, the company evaluates where price increases may be needed. In exports, customers are conscious of global API prices and do not expect the company to absorb all increases.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Plant 6 commercialization | Mechanical completion done; commercialization on track | H1 FY27 |
| Revenue capacity post-Plant 6 | ~₹1,000 cr (ex-injectables at ₹100 cr), with 10-15% efficiency upside | As plant commercializes |
| Organic capex | No organic capex expected beyond maintenance capex | FY27 |
| Next capacity addition | Additional capacity possible if very good numbers delivered | FY28 |
| Working capital range | No significant variation expected from current 20-25 days | Ongoing |
| EU GMP approval | Readiness and preparedness on track; timeline not disclosed | No timeline given |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹238 cr, +18% YoY |
| FY26 revenue | ₹904 cr, +19% YoY |
| CDMO revenue | ₹176 cr, +20% YoY; 73% of total revenue |
| Trade generics & institutional revenue | ₹46 cr, flat YoY; FY26 grew 13% to ₹195 cr |
| Export revenue | ₹17 cr, +67% YoY; FY26 grew 40% to ₹46 cr |
| Reported EBITDA | ₹25 cr, FY26 grew 11% to ₹105 cr |
| Adjusted EBITDA | ₹33 cr, 13.6% margin; FY26 ₹121 cr, 13.4% margin |
| Reported PAT | ₹16 cr, FY26 rose 9% to ₹66 cr |
| Adjusted PAT | ₹23 cr, 9.7% margin; FY26 ₹83 cr, 9.2% margin |
| EPS (FY26, post-listing highest) | ₹31.60 |
| ROCE and ROE | Above 25% (FY26) |
| Net operating cash flow (FY26) | ₹105 cr |
| Net liquidity position | ₹251 cr (FY26 closing) |
| Customer concentration | Top customer 6.5%, top 10 at 32%, top 20 at 40-41% of revenue (FY26) |
| Working capital days | 20–25 days, reduced from ~40 days; sustained for ~3 years |
| Plant 6 peak revenue potential | ~₹1,000 cr (excluding injectables ~₹100 cr); company-level capacity ready for ~₹1,100 cr |
| Capacity expansion headroom | 10–15% further efficiency unlock possible beyond stated peak levels |
| Dividend proposed (FY26) | ₹6.3 per share, total ₹13 cr |
| Buyback completed | ₹47 cr, without promoter participation |